Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | GLP1R | P43220 | 5/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | CPA2 | P48052 | 1/20 | 0.31 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | FURIN | P09958 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22388632 | 0.97 | FOLH1 (0.37) | FOLH1HDAC1HDAC7PSMB5HTRA1 | |
| SCHEMBL19732156 | 0.87 | FOLH1 (0.37) | FOLH1HDAC1HDAC7 | |
| SCHEMBL25245450 | 0.87 | FOLH1 (0.35) | FOLH1GLP1RHDAC1HDAC7 | |
| SCHEMBL25242024 | 0.86 | FOLH1 (0.37) | FOLH1HDAC1HDAC7 | |
| SCHEMBL25242026 | 0.86 | FOLH1 (0.37) | FOLH1HDAC1HDAC7 | |
| SCHEMBL31681443 | 0.80 | SIRT1 (0.37) | GLP1RALBCPA1CPA2CPA4 | |
| SCHEMBL27190126 | 0.77 | HDAC8 (0.34) | GLP1RHDAC1HDAC7 | |
| SCHEMBL27189832 | 0.77 | HDAC8 (0.34) | GLP1RHDAC1HDAC7 | |
| SCHEMBL25218460 | 0.76 | HDAC8 (0.36) | GLP1RHDAC1HDAC7 | |
| SCHEMBL26066853 | 0.75 | HDAC8 (0.39) | HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541047-B2 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | IMMUNOMEDICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20200316054-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20190167805-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316054-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | CD74, CD2, CD22 | FOLH1 142/4885GLP1R 2022/4885HDAC1 3175/4885 |
| US-11541047-B2 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | CD74, CD2, CD22 | FOLH1 142/4885GLP1R 2022/4885HDAC1 3175/4885 |
| US-20190167805-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, CD44, DNPEP | FOLH1 5/4885GLP1R 4061/4885HDAC1 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.